ArticleJournal of ginseng research2025
Compound K-enriched Korean red ginseng prevents lung cancer progression by targeting cancer cells and fibroblasts.
Article in Journal of ginseng research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The roles of ginseng and ginsenosides for immune regulation: Relation to immunometabolic responses.Journal of ginseng research · 2026Review
- Ginsenosides fromJournal of ginseng research · 2026Review
- Review
- Acylcarnitines in Cancer Metabolism: Mechanistic Insights and Stratification Potential.Cancers · 2026Review
- Cost analysis and cost-effectiveness of traditional Chinese medicine in lung cancer: a scoping review.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the efficacy of anticancer drugs, patients frequently experience relapse, metastasis, and resistance. A promising therapeutic approach not only targets cancer cell growth but also modulates cancer-associated fibroblasts, which support malignancies. Compound K (CK), a metabolite derived from red ginseng, has demonstrated anticancer properties. Recently, we developed a CK-enriched red ginseng extract (CKP) and explored its potential to suppress lung cancer by inhibiting cancer cell proliferation and inactivating fibroblasts. Methods: To evaluate the Results: CKP significantly reduced the proliferation and invasiveness of TGF-β1-stimulated A549 cells, demonstrating its potential to inactivate lung fibroblasts. Additionally, CKP inhibited the secretion of cytokines, such as interleukin-6, interleukin-8, and TGF-β1, by activated fibroblasts. Conclusion: In conclusion, CKP effectively induced apoptosis in lung cancer cells, suppressed metastasis, and inactivated fibroblasts, thereby preventing cancer invasion and reducing extracellular matrix production, highlighting its potential as a novel anticancer agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.